Online inquiry

IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13402MR)

This product GTTS-WQ13402MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13402MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12020MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ15798MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ8971MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ7213MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ672MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ7873MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ7277MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ15093MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW